166 related articles for article (PubMed ID: 35634752)
1. Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Deng JH; Zhang JX
Clin Cardiol; 2022 Jul; 45(7):685-686. PubMed ID: 35634752
[No Abstract] [Full Text] [Related]
2. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
3. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
Alten R; Mischkewitz M; Nitschmann S
Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
[No Abstract] [Full Text] [Related]
4. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Wang M; Zhang Y; Zhang M; Li H; Wen C; Zhao T; Xie Z; Sun J
Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Gao L; Wang B; Pan Y; Lu Y; Cheng R
Clin Cardiol; 2021 Jul; 44(7):907-916. PubMed ID: 34013998
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland.
Quilis N; Vela P; Blanco Cáceres BA; Diaz-Torne C; Calvo-Aranda E; Sivera F; Prada-Ojeda A; Pérez Ruiz F; Pascual E; Andrés M
Ann Rheum Dis; 2022 Jul; 81(7):e124. PubMed ID: 32616605
[No Abstract] [Full Text] [Related]
7. Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis".
Gao L; Wang B; Cheng R
Clin Cardiol; 2022 Jul; 45(7):687-690. PubMed ID: 35634754
[No Abstract] [Full Text] [Related]
8. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Wang S
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.
Xie H; Hu N; Pan T; Wu JC; Yu M; Wang DC
BMC Pharmacol Toxicol; 2023 Dec; 24(1):79. PubMed ID: 38098046
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
Deng JH; Lai PH; Xie LS; Qiu SS; Qiu DS; Zhang JX
Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
[TBL] [Abstract][Full Text] [Related]
11. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
12. Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills
Singh JA
Ann Rheum Dis; 2022 Jul; 81(7):e125. PubMed ID: 32616606
[No Abstract] [Full Text] [Related]
13. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat for the chronic management of hyperuricemia in patients with gout.
Chinchilla SP; Urionaguena I; Perez-Ruiz F
Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
[TBL] [Abstract][Full Text] [Related]
15. Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Ma KS; Wei JC; Chung WH
Ann Rheum Dis; 2022 Jun; 81(6):e107. PubMed ID: 32561605
[No Abstract] [Full Text] [Related]
16. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
[TBL] [Abstract][Full Text] [Related]
17. Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma
Singh JA
Ann Rheum Dis; 2022 Jun; 81(6):e108. PubMed ID: 32561599
[No Abstract] [Full Text] [Related]
18. A word of caution regarding Febuxostat.
Ochani RK; Yasmin F; Batra S; Asad A
J Pak Med Assoc; 2019 Dec; 69(12):1930. PubMed ID: 31853136
[No Abstract] [Full Text] [Related]
19. `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
Jeong H; Choi E; Suh A; Yoo M; Kim B
Rheumatol Int; 2023 Feb; 43(2):265-281. PubMed ID: 36346443
[TBL] [Abstract][Full Text] [Related]
20. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
